Provenienza dei contatti di primo grado di Jan Smeitink
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
Khondrion BV
 Khondrion BV Pharmaceuticals: MajorHealth Technology Khondrion BV is a Dutch clinical-stage biopharmaceutical company that focuses on discovering and developing therapies for mitochondrial diseases. The company is based in Nijmegen, Netherlands, and was founded in 2012 by Jan Smeitink, who has been the CEO since then. The company's lead drug candidate, sonlicromanol, is a first-in-class, oral small molecule that targets key underlying mechanisms of primary mitochondrial disease. The compound has been granted orphan drug designations for the treatment of various mitochondrial diseases. Khondrion collaborates with a clinical and academic network and patient organizations internationally to accelerate the discovery and development of its potential medicines.
2
| Holding Company | Pharmaceuticals: Major | 2 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Jan Smeitink tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
Wyeth Pharmaceuticals LLC
 Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal | |
| ECONOCOM GROUP SE | Information Technology Services | Director/Board Member | |
Econocom International BV
 Econocom International BV Electronics DistributorsDistribution Services Econocom International BV operates as a financial holding company with interests in computer equipment. The company was founded in 1985 and is headquartered in Nieuwegein, the Netherlands. | Electronics Distributors | President | |
| University of Groningen | College/University | Undergraduate Degree | |
| Rabobank West-Betuwe | Director/Board Member | ||
| Zuijdplas Beleggingen | Corporate Officer/Principal | ||
| Kaacel BV | Chairman | ||
Moonlake Immunotherapeutics AG
 Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The company is based in Zug, Switzerland. The company was founded in 2021 by Arnout Ploos van Amstel, Jorge Santos da Silva, Kristian Reich. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | Pharmaceuticals: Major | Founder |
Statistiche
Distribuzione geografica
| Paesi Bassi | 6 |
| Svizzera | 3 |
| Stati Uniti | 2 |
| Belgio | 2 |
| Isole Cayman | 2 |
Settori
| Health Technology | 4 |
| Technology Services | 2 |
| Distribution Services | 2 |
| Consumer Services | 2 |
| Finance | 2 |
Posizioni
| Director/Board Member | 5 |
| Corporate Officer/Principal | 3 |
| Chief Operating Officer | 2 |
| President | 1 |
| Chairman | 1 |
Contatti più connessi
- Borsa valori
- Insiders
- Jan Smeitink
- Connessioni Società
